ORMP logo

Oramed Pharmaceuticals (ORMP) Cash From Financing

Annual CFF

$51.98 M
+$41.20 M+382.22%

December 1, 2023

Summary

Performance

1-Year Change

+382.22%

3-Year Change

+299.8%

5-Year Change

+100%

15-Year Change

+3177.3%

ORMP Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

78.71%
ORMP annual cash flow from financing activities is higher than 78.71% of companies in Healthcare sector

High & Low

All-time High

$102.89 M
ORMP annual cash flow from financing activities is currently -49.48% below its historical high of $102.89 million

3-Year Low

$10.78 M
ORMP annual cash flow from financing activities is currently +382.22% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
ORMP previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

May 9, 2025
ORMP next annual earnings announcement is scheduled for May 9, 2025

OtherORMPcash flowmetrics:

Annual CFI

-$73.04 M
ORMP annual cash flow from investing activities is -$73.04 million

Annual CFO

-$10.29 M
ORMP annual cash flow from operations is -$10.29 million

Annual FCF

-$10.55 M
ORMP annual free cash flow is -$10.55 million

Annual CAPEX

$254.00 K
ORMP annual capital expenditures is $254.00 thousand

Quarterly CFF

-$1.29 M
+$29.26 M+95.77%

September 1, 2024

Summary

Performance

3-Month Change

+95.77%

1-Year Change

+94.84%

3-Year Change

-129000%

5-Year Change

-100%

ORMP Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

19.96%
ORMP quarterly cash flow from financing activities is higher than 19.96% of companies in Healthcare sector

High & Low

All-time High

$74.55 M
ORMP quarterly cash flow from financing activities is currently -101.73% below its historical high of $74.55 million

3-Year Low

-$30.55 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
ORMP previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

May 9, 2025
ORMP next earnings announcement is scheduled for May 9, 2025

OtherORMPcash flowmetrics:

Quarterly CFI

-$34.26 M
ORMP quarterly cash flow from investing activities is -$34.26 million

Quarterly CFO

-$7.10 M
ORMP quarterly cash flow from operations is -$7.10 million

Quarterly FCF

-$7.11 M
ORMP quarterly free cash flow is -$7.11 million

Quarterly CAPEX

-
ORMP quarterly capital expenditures value is unknown

TTM CFF

-$75.84 M
-$75.84 M-3791950.00%

September 1, 2024

Summary

Performance

3-Month Change

-3791950%

1-Year Change

-245.91%

3-Year Change

-164.34%

5-Year Change

-583492.31%

ORMP TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

9.11%
ORMP TTM cash flow from financing activities is higher than 9.11% of companies in Healthcare sector

High & Low

All-time High

$162.87 M
ORMP TTM cash flow from financing activities is currently -146.57% below its historical high of $162.87 million

3-Year Low

-$75.84 M
ORMP TTM cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
ORMP previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

May 9, 2025
ORMP next earnings announcement is scheduled for May 9, 2025

OtherORMPcash flowmetrics:

TTM CFI

$120.39 M
ORMP TTM cash flow from investing activities is $120.39 million

TTM CFO

-$7.92 M
ORMP TTM cash flow from operations is -$7.92 million

TTM FCF

-$7.93 M
ORMP TTM free cash flow is -$7.93 million

TTM CAPEX

-
ORMP TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ORMP Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+382.2%+94.8%-245.9%
3 y3 years+299.8%-10000.0%-164.3%
5 y5 years+100.0%-100.0%-10000.0%

ORMP Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-14.2%+382.2%-101.7%+95.8%-146.6%at low
5 y5-year-49.5%-100.0%-101.7%+95.8%-146.6%at low
alltimeall time-49.5%-100.0%-101.7%+95.8%-146.6%at low

Oramed Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
-$1.29 M(-95.8%)
-$75.84 M(>+9900.0%)
Jun 2024
-
-$30.55 M(+60.8%)
-$2000.00(-100.0%)
Mar 2024
-
-$19.00 M(-24.0%)
$30.55 M(-41.2%)
Dec 2023
$51.98 M(+382.2%)
-$25.00 M(-133.5%)
$51.98 M(-36.0%)
Sep 2023
-
$74.55 M(>+9900.0%)
$81.15 M(+643.3%)
Jun 2023
-
$0.00(-100.0%)
$10.92 M(+0.0%)
Mar 2023
-
$2.43 M(-41.8%)
$10.92 M(+1.3%)
Dec 2022
$10.78 M(-82.2%)
$4.17 M(-3.2%)
$10.78 M(-84.0%)
Sep 2022
-
$4.31 M(<-9900.0%)
$67.17 M(-43.0%)
Jun 2022
-
-$1000.00(-100.0%)
$117.88 M(-15.6%)
Mar 2022
-
$2.29 M(-96.2%)
$139.73 M(-14.2%)
Dec 2021
$60.57 M(-41.1%)
-
-
Nov 2021
-
$60.56 M(+10.1%)
$162.87 M(+58.3%)
Aug 2021
$102.89 M(+691.4%)
$55.02 M(+151.8%)
$102.89 M(+108.5%)
May 2021
-
$21.86 M(-14.0%)
$49.35 M(+4.0%)
Feb 2021
-
$25.43 M(+4239.1%)
$47.47 M(+94.9%)
Dec 2020
$13.00 M(-45.3%)
-
-
Nov 2020
-
$586.00 K(-60.4%)
$24.36 M(+2.4%)
Aug 2020
$23.79 M(>+9900.0%)
$1.48 M(-92.6%)
$23.79 M(+6.6%)
May 2020
-
$19.98 M(+762.7%)
$22.31 M(+857.8%)
Feb 2020
-
$2.32 M(>+9900.0%)
$2.33 M(>+9900.0%)
Nov 2019
-
$13.00 K(>+9900.0%)
$13.00 K(>+9900.0%)
Aug 2019
$0.00(-100.0%)
$0.00(0.0%)
$0.00(-100.0%)
May 2019
-
$0.00(0.0%)
$16.49 M(-1.7%)
Feb 2019
-
$0.00(0.0%)
$16.78 M(-4.1%)
Nov 2018
-
$0.00(-100.0%)
$17.49 M(-22.8%)
Aug 2018
$22.65 M(+1328.4%)
$16.49 M(+5727.9%)
$22.65 M(+205.0%)
May 2018
-
$283.00 K(-60.6%)
$7.43 M(+4.0%)
Feb 2018
-
$718.00 K(-86.1%)
$7.14 M(+11.2%)
Nov 2017
-
$5.16 M(+307.6%)
$6.43 M(+305.2%)
Aug 2017
$1.59 M(-86.8%)
$1.27 M(>+9900.0%)
$1.59 M(+268.0%)
May 2017
-
$0.00(0.0%)
$431.00 K(-10.8%)
Feb 2017
-
$0.00(-100.0%)
$483.00 K(-96.0%)
Nov 2016
-
$320.00 K(+188.3%)
$12.20 M(+1.3%)
Aug 2016
$12.04 M(+23.9%)
$111.00 K(+113.5%)
$12.04 M(-28.4%)
May 2016
-
$52.00 K(-99.6%)
$16.81 M(+0.3%)
Feb 2016
-
$11.72 M(+7043.9%)
$16.76 M(+231.7%)
Nov 2015
-
$164.00 K(-96.6%)
$5.05 M(-48.0%)
DateAnnualQuarterlyTTM
Aug 2015
$9.72 M(-41.6%)
$4.88 M(>+9900.0%)
$9.72 M(+100.7%)
May 2015
-
$0.00(-100.0%)
$4.84 M(-2.9%)
Feb 2015
-
$8000.00(-99.8%)
$4.99 M(-76.8%)
Nov 2014
-
$4.83 M(>+9900.0%)
$21.47 M(+29.0%)
Aug 2014
$16.64 M(+185.7%)
$2000.00(-98.6%)
$16.64 M(-20.8%)
May 2014
-
$143.00 K(-99.1%)
$21.01 M(+0.7%)
Feb 2014
-
$16.50 M(>+9900.0%)
$20.87 M(+378.0%)
Nov 2013
-
$0.00(-100.0%)
$4.37 M(-25.0%)
Aug 2013
$5.82 M(+66.9%)
$4.37 M(>+9900.0%)
$5.82 M(+17.9%)
May 2013
-
$0.00(-100.0%)
$4.94 M(0.0%)
Feb 2013
-
-$7500.00(-100.5%)
$4.94 M(-0.2%)
Nov 2012
-
$1.46 M(-58.2%)
$4.95 M(+41.8%)
Aug 2012
$3.49 M(-5.6%)
$3.49 M(>+9900.0%)
$3.49 M(>+9900.0%)
May 2012
-
$0.00(0.0%)
$0.00(-100.0%)
Feb 2012
-
$0.00(0.0%)
$588.20 K(-82.7%)
Nov 2011
-
$0.00(0.0%)
$3.39 M(-8.1%)
Aug 2011
$3.69 M(>+9900.0%)
$0.00(-100.0%)
$3.69 M(0.0%)
May 2011
-
$588.20 K(-79.0%)
$3.69 M(+18.9%)
Feb 2011
-
$2.81 M(+835.3%)
$3.11 M(+935.3%)
Nov 2010
-
$300.00 K(>+9900.0%)
$300.00 K(>+9900.0%)
Aug 2010
$0.00(-100.0%)
$0.00(0.0%)
$0.00(0.0%)
May 2010
-
$0.00(0.0%)
$0.00(0.0%)
Feb 2010
-
$0.00(0.0%)
$0.00(0.0%)
Nov 2009
-
$0.00(0.0%)
$0.00(-100.0%)
May 2009
-
$0.00(0.0%)
$2.98 M(-40.7%)
Nov 2008
-
$0.00(-100.0%)
$5.03 M(0.0%)
Aug 2008
$5.03 M(+113.6%)
$2.98 M(+46.0%)
$5.03 M(+57.2%)
May 2008
-
$2.04 M(>+9900.0%)
$3.20 M(+43.5%)
Feb 2008
-
$0.00(0.0%)
$2.23 M(-5.3%)
Nov 2007
-
$0.00(-100.0%)
$2.35 M(0.0%)
Aug 2007
$2.35 M(+337.9%)
$1.16 M(+7.4%)
$2.35 M(+64.8%)
May 2007
-
$1.07 M(+760.0%)
$1.43 M(+117.9%)
Feb 2007
-
$125.00 K(>+9900.0%)
$655.90 K(+23.2%)
Nov 2006
-
$0.00(-100.0%)
$532.40 K(-1.0%)
Aug 2006
$537.80 K(+1231.2%)
$229.00 K(-24.1%)
$537.80 K(+74.2%)
May 2006
-
$301.90 K(>+9900.0%)
$308.80 K(+4375.4%)
Feb 2006
-
$1500.00(-72.2%)
$6900.00(+27.8%)
Nov 2005
-
$5400.00
$5400.00
Aug 2005
$40.40 K
-
-

FAQ

  • What is Oramed Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Oramed Pharmaceuticals?
  • What is Oramed Pharmaceuticals annual CFF year-on-year change?
  • What is Oramed Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Oramed Pharmaceuticals?
  • What is Oramed Pharmaceuticals quarterly CFF year-on-year change?
  • What is Oramed Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Oramed Pharmaceuticals?
  • What is Oramed Pharmaceuticals TTM CFF year-on-year change?

What is Oramed Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of ORMP is $51.98 M

What is the all time high annual CFF for Oramed Pharmaceuticals?

Oramed Pharmaceuticals all-time high annual cash flow from financing activities is $102.89 M

What is Oramed Pharmaceuticals annual CFF year-on-year change?

Over the past year, ORMP annual cash flow from financing activities has changed by +$41.20 M (+382.22%)

What is Oramed Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of ORMP is -$1.29 M

What is the all time high quarterly CFF for Oramed Pharmaceuticals?

Oramed Pharmaceuticals all-time high quarterly cash flow from financing activities is $74.55 M

What is Oramed Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, ORMP quarterly cash flow from financing activities has changed by +$23.71 M (+94.84%)

What is Oramed Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of ORMP is -$75.84 M

What is the all time high TTM CFF for Oramed Pharmaceuticals?

Oramed Pharmaceuticals all-time high TTM cash flow from financing activities is $162.87 M

What is Oramed Pharmaceuticals TTM CFF year-on-year change?

Over the past year, ORMP TTM cash flow from financing activities has changed by -$127.82 M (-245.91%)